| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.027 | 0.9 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | 0.021 | 0.9 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |